ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Roche ends development of SMA drug olesoxime

by Lisa M. Jarvis
June 10, 2018 | APPEARED IN VOLUME 96, ISSUE 24

 

Roche has ended development of olesoxime, a small molecule designed to protect nerve cells in spinal muscular atrophy. In 2015, the big pharma firm paid roughly $140 million to acquire olesoxime from Trophos, and it had hoped to begin a Phase III study of the compound later this year. But in a letter to SMA patient advocacy groups, Roche said it had struggled with the formulation of the drug. And because of newly available treatments for SMA, the company chose to end its efforts in the area.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment